Aktuellt
SENASTE
Redeye presents its preview of Sedana Medical’s Q1 2024 report, due on April 25. Q1 marks the first full quarter with MHRA approval in the UK and pricing and reimbursement in place in Spain, two factors we believe could ignite sales further during the year. We make no changes to our estimates or fair value range ahead of the report.
LÄS MER
